About

Gordon & Rees E-Discovery Law Blog

The Gordon & Rees E-Discovery Files Blog provides news and updates on developments and issues in the constantly and quickly evolving field of e-discovery. The blog is intended to be a trusted go-to resource for clients with both common and nuanced e-discovery concerns. It includes state of the art guidance on how to navigate the complex maze of ever changing state and federal e-discovery rules.

Co-Editors:

lilly-jeffreyJeff Lilly is a litigator with over twenty years of experience on behalf of corporate clients in state and federal courts in Texas and throughout the United States, including in national MDLs. Jeff’s practice includes representing Fortune 500 clients in mass tort litigation settings to individual corporate clients in a wide range of matters, including product liability, commercial litigation, premises liability and director & officer liability. This breadth of experience allows Jeff to counsel clients in early options for resolving cases, either through aggressive or creative early motion practice, informal negotiation, or formal alternative dispute resolution. Also, as co-chair of the firm’s e-discovery practice group, Jeff advises on significant e-discovery matters and is a frequent author and speaker on e-discovery issues and developments.

cary-andrewAndrew Cary is an experienced litigation partner at Gordon & Rees who specializes in representing businesses and individuals in a broad range of complex litigation matters, including cases involving drug and medical device product liability, toxic tort matters, qui tam actions, False Claims Act, business disputes, breach of contract and professional liability. He has extensive experience with motion practice, deposition discovery, dispositive motions, major document discovery, alternative dispute resolution, including mediation, FINRA and FIFRA arbitrations and trial preparation. Andrew is co-chair of the Electronic Discovery Group at Gordon & Rees and enjoys presenting on various topics with a focus on key regulatory issues related to drugs and medical devices as well as deposition discovery during litigation.